(-1.57%) 5 035.69 points
(-1.49%) 37 816 points
(-2.04%) 15 658 points
(-1.20%) $81.64
(-2.76%) $1.974
(-2.26%) $2 304.40
(-4.03%) $26.55
(-1.42%) $947.85
(0.49%) $0.937
(1.10%) $11.10
(0.53%) $0.800
(0.15%) $93.44
Live Chart Being Loaded With Signals
Alphamab Oncology, a clinical stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of oncology biologics...
Stats | |
---|---|
今日成交量 | 1.32M |
平均成交量 | 2.75M |
市值 | 4.58B |
EPS | HKD0 ( 2023-08-23 ) |
Last Dividend | HKD0 ( N/A ) |
Next Dividend | HKD0 ( N/A ) |
P/E | -19.79 |
ATR14 | HKD0.0200 (0.42%) |
音量 相关性
Alphamab Oncology 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Alphamab Oncology 相关性 - 货币/商品
Alphamab Oncology 财务报表
Annual | 2023 |
营收: | HKD218.77M |
毛利润: | HKD163.54M (74.75 %) |
EPS: | HKD-0.220 |
FY | 2023 |
营收: | HKD218.77M |
毛利润: | HKD163.54M (74.75 %) |
EPS: | HKD-0.220 |
FY | 2022 |
营收: | HKD166.85M |
毛利润: | HKD122.64M (73.50 %) |
EPS: | HKD-0.350 |
FY | 2021 |
营收: | HKD146.02M |
毛利润: | HKD142.99M (97.93 %) |
EPS: | HKD-0.444 |
Financial Reports:
No articles found.
Alphamab Oncology
Alphamab Oncology, a clinical stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of oncology biologics. Its product pipeline includes KN046, a bispecific monoclonal antibody (BsAb) immune checkpoint inhibitor, which is in pivotal Phase III clinical trials that targets clinically-validated immune checkpoints, including programmed death ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4); and KN026, a next generation anti-human epidermal growth factor receptor 2 (HER2) BsAb that is in Phase II clinical trials for treating HER2-positive breast cancers and I/II clinical trial treatment of heavily pre-treated breast cancers, as well as Phase II clinical trial for HER2-positive solid tumors. The company's product pipeline also comprises KN019, a CTLA-4-based immunosuppressant fusion protein, which is in Phase II clinical trial with potential broad applications in both auto-immune diseases and oncology treatment-induced immune disorders; and KN035, an injectable PD-L1 inhibitor that has completed phase II pivotal clinical trials for deficient mismatch repair/microsatellite instability-high solid tumors, and is in Phase III pivotal trials for biliary tract cancer. In addition, its product pipeline also includes KN052 an innovative PD-L1/OX40 bispecific antibody, which is in phase Ia/Ib clinical trial for the treatment of advanced solid tumors. The company was founded in 2008 and is headquartered in Suzhou, the People's Republic of China.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。